In vitro Dissolution Enhancement and Development of Pre-Programmed Pulsatile Delivery System of BCS-II Drug: Lornoxicam

Author(s): U. Mohan Kumar* and Y. Sudhakar

Abstract: The intension of the present investigation was to enhance the solubility and to prepare pulsatile delivery system for BCS-II drug- lornoxicam for the treatment of rheumatoid arthritis (RA).To achieve the aim, poorely soluble drug primarily converted into sild dispersion form using highly soluble hydrophilic soluble carriers (PVPVA 64, SOLUPLUS) and surfactants ( LUTROL F68, LUTROL F85, LUTROL F127), then sold dispersion converted to fast dissolving tablets using super disintegrants to fasten the dissolution of drug in GIT. In order to achieve chronological release, film coated pulsatile release tablets were prepared by employing HPMC E15 as swelling agent, Konjac glucomannan triacetate as membrane former, Eudragit L100-50 as pore former and triethyl citrate as plasticizer. A 3-factor, 3-level Box-Behnken design (BBD) was utilised to optimise the formulation and to produce second order polynomial equations to predict lag time. The BBD optimization process and overlay plots has predicted the levels of independent variables A, B, and C (20% w/w, 24.72% w/w, 10.68% w/w respectively) to achieve targeted responses lag Time (6 hr) and T75% (6.3 hr) and observed the same with 0.04 % relative error.

PAGES: 641-655  |  30 VIEWS  42 DOWNLOADS